WallStSmart
IMVT

Immunovant Inc

NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY

$29.06
-4.78% today

Updated 2026-06-05

Market cap
$6.90B
P/E ratio
P/S ratio
EPS (TTM)
$-2.77
Dividend yield
52W range
$14 – $36
Volume
1.9M

Immunovant Inc (IMVT) Financial statements

SEC filings — annual and quarterly data.

Balance sheet — annual

Item201820192020202120222023202420252026
Total assets$113170.00$405000.00$109.39M$412.49M$515.56M$405.84M$666.71M$776.22M$957.57M
Cash & equivalents$325000.00$100.57M$400.15M$493.82M$376.53M$635.37M$713.97M$902.11M
Current assets$113170.00$325000.00$109.08M$409.01M$512.93M$404.33M$665.77M$767.66M$948.82M
Total liabilities$1.61M$380448.00$15.32M$21.01M$45.74M$43.34M$48.95M$68.78M$104.97M
Current liabilities$1.61M$380448.00$15.32M$18.77M$44.52M$43.30M$48.61M$68.78M$104.42M
Long-term debt
Shareholder equity$-1.50M$24552.00$94.07M$391.48M$469.82M$362.49M$617.76M$707.45M$852.59M
Retained earnings$-448.00$-91.23M$-198.66M$-355.39M$-566.35M$-825.68M$-1.24B$-1.75B
Accounts receivable$2.96M$3.04M$1.14M$12.86M$885000.00$5.50M$2.51M$3.95M
Inventory$0.00$0.00$0.00$-24.90M
Goodwill

Frequently asked questions

How much free cash flow does IMVT generate?

IMVT produced $-407.32M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is IMVT's balance sheet healthy?

IMVT holds $902.11M in cash and equivalents against — in long-term debt, on $852.59M of shareholder equity. That debt is best read against the cash flow the business throws off each year.